Skip to main content

Management of Well-Differentiated High-Grade (G3) Neuroendocrine Tumors

Current Treatment Options in Oncology volume 20, Article number: 74 (2019) Cite this article

Opinion statement

In 2017, the World Health Organization (WHO) classification for pancreatic NET was updated to include a new category of well-differentiated high-grade (Ki 67 > 20%) pancreatic tumors (NET G3), distinct from high-grade poorly differentiated neuroendocrine carcinoma (NEC). NET G3 are considered a molecularly, radiologically, and prognostically distinct entity compared to NEC and NET G1/G2. The optimal first-line management in NET G3 and sequencing therapies remains a challenge awaiting future trials taking into consideration the unique characteristics of this category. In this review, we aim to summarize the current evidence in the management of NET G3.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Fig. 1

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26(18):3063–72. https://doi.org/10.1200/JCO.2007.15.4377.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Milione M, Maisonneuve P, Spada F, Pellegrinelli A, Spaggiari P, Albarello L, et al. The clinicopathologic heterogeneity of grade 3 gastroenteropancreatic neuroendocrine neoplasms: morphological differentiation and proliferation identify different prognostic categories. Neuroendocrinology. 2017;104(1):85–93. https://doi.org/10.1159/000445165.

    CAS  Article  PubMed  Google Scholar 

  3. Rindi GAR, Bosman FT, Capella C, Klimstra DS, Komminoth KG, Solcia P, et al. Nomenclature and classification of digestive neuroendocrine tumours; World Health Organization Classification of Tumours, Pathology and Genetics of Tumours of the Digestive System. Lyon: International Agency for Research on Cancer (IARC). WHO Press; 2010.

    Google Scholar 

  4. Dasari A, Mehta K, Byers LA, Sorbye H, Yao JC. Comparative study of lung and extrapulmonary poorly differentiated neuroendocrine carcinomas: a SEER database analysis of 162,983 cases. Cancer. 2018;124(4):807–15. https://doi.org/10.1002/cncr.31124.

    Article  PubMed  Google Scholar 

  5. Faggiano A, Sabourin JC, Ducreux M, Lumbroso J, Duvillard P, Leboulleux S, et al. Pulmonary and extrapulmonary poorly differentiated large cell neuroendocrine carcinomas: diagnostic and prognostic features. Cancer. 2007;110(2):265–74. https://doi.org/10.1002/cncr.22791.

    CAS  Article  PubMed  Google Scholar 

  6. Madeira I, Terris B, Voss M, Denys A, Sauvanet A, Flejou JF, et al. Prognostic factors in patients with endocrine tumours of the duodenopancreatic area. Gut. 1998;43(3):422–7.

    CAS  Article  Google Scholar 

  7. Rindi G, Azzoni C, La Rosa S, Klersy C, Paolotti D, Rappel S, et al. ECL cell tumor and poorly differentiated endocrine carcinoma of the stomach: prognostic evaluation by pathological analysis. Gastroenterology. 1999;116(3):532–42.

    CAS  Article  Google Scholar 

  8. Travis WD, Rush W, Flieder DB, Falk R, Fleming MV, Gal AA, et al. Survival analysis of 200 pulmonary neuroendocrine tumors with clarification of criteria for atypical carcinoid and its separation from typical carcinoid. Am J Surg Pathol. 1998;22(8):934–44.

    CAS  Article  Google Scholar 

  9. • Singhi AD, Klimstra DS. Well-differentiated pancreatic neuroendocrine tumours (PanNETs) and poorly differentiated pancreatic neuroendocrine carcinomas (PanNECs): concepts, issues and a practical diagnostic approach to high-grade (G3) cases. Histopathology. 2018;72(1):168–77. https://doi.org/10.1111/his.13408Study examining the challenges and issues with diagnostic approach to high-grade 3 neuroendocrine tumors.

    Article  PubMed  Google Scholar 

  10. Basturk O, Yang Z, Tang LH, Hruban RH, Adsay V, McCall CM, et al. The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogenous and includes both well differentiated and poorly differentiated neoplasms. Am J Surg Pathol. 2015;39(5):683–90. https://doi.org/10.1097/PAS.0000000000000408.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Kim JY, Hong SM. Recent updates on neuroendocrine tumors from the gastrointestinal and pancreatobiliary tracts. Arch Pathol Lab Med. 2016;140(5):437–48. https://doi.org/10.5858/arpa.2015-0314-RA.

    CAS  Article  PubMed  Google Scholar 

  12. Sorbye H, Strosberg J, Baudin E, Klimstra DS, Yao JC. Gastroenteropancreatic high-grade neuroendocrine carcinoma. Cancer. 2014;120(18):2814–23. https://doi.org/10.1002/cncr.28721.

    CAS  Article  PubMed  Google Scholar 

  13. Lloyd RVOR, Kloppel G, Rosai J. WHO classification of tumours of endocrine organs (World Health Organization Classification of Tumors) 4th Edition: IARC Press; 2017.

  14. Apostolidis L JD, Winkler E.C. Treatment outcomes for well differentiated grade 3 neuroendocrine tumors (NET G3). 2018.

  15. •• Sorbye H, Baudin E, Borbath I, Caplin M, Chen J, Cwikla JB, et al. Unmet needs in high-grade gastroenteropancreatic neuroendocrine neoplasms (WHO G3). Neuroendocrinology. 2019;108(1):54–62. https://doi.org/10.1159/000493318Excellent review of the high-grade neuroendocrine tumors in general.

    CAS  Article  PubMed  Google Scholar 

  16. Sorbye H, Baudin E, Perren A. The problem of high-grade gastroenteropancreatic neuroendocrine neoplasms: well-differentiated neuroendocrine tumors, neuroendocrine carcinomas, and beyond. Endocrinol Metab Clin N Am. 2018;47(3):683–98. https://doi.org/10.1016/j.ecl.2018.05.001.

    Article  Google Scholar 

  17. Heetfeld M, Chougnet CN, Olsen IH, Rinke A, Borbath I, Crespo G, et al. Characteristics and treatment of patients with G3 gastroenteropancreatic neuroendocrine neoplasms. Endocr Relat Cancer. 2015;22(4):657–64. https://doi.org/10.1530/ERC-15-0119.

    CAS  Article  PubMed  Google Scholar 

  18. Furnace MMG, Rundell C, Shah R, Luong TV, Krell D, Meyer T, et al. High Grade (G3) Gastro-entero-pancreatic neuroendocrine neoplasms: should the new WHO classification apply to all? ENET; 2018. Presented at the 2019 16th annual conference of the European Neuroendocrine Tumor Society (ENETS) in Barcelona, Spain, March 2019.

  19. Han X, Xu X, Ma H, Ji Y, Wang D, Kuang T, et al. Clinical relevance of different WHO grade 3 pancreatic neuroendocrine neoplasms based on morphology. Endocr Connect. 2018;7(2):355–63. https://doi.org/10.1530/EC-17-0388.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Tang LH, Untch BR, Reidy DL, O’Reilly E, Dhall D, Jih L, et al. Well-differentiated neuroendocrine tumors with a morphologically apparent high-grade component: a pathway distinct from poorly differentiated neuroendocrine carcinomas. Clin Cancer Res. 2016;22(4):1011–7. https://doi.org/10.1158/1078-0432.CCR-15-0548.

    CAS  Article  PubMed  Google Scholar 

  21. Sorbye H, Welin S, Langer SW, Vestermark LW, Holt N, Osterlund P, et al. Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study. Ann Oncol. 2013;24(1):152–60. https://doi.org/10.1093/annonc/mds276.

    CAS  Article  PubMed  Google Scholar 

  22. Raj N, Valentino E, Capanu M, Tang LH, Basturk O, Untch BR, et al. Treatment response and outcomes of grade 3 pancreatic neuroendocrine neoplasms based on morphology: well differentiated versus poorly differentiated. Pancreas. 2017;46(3):296–301. https://doi.org/10.1097/MPA.0000000000000735.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Jiao Y, Shi C, Edil BH, de Wilde RF, Klimstra DS, Maitra A, et al. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science. 2011;331(6021):1199–203. https://doi.org/10.1126/science.1200609.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  24. Shi C, Klimstra DS. Pancreatic neuroendocrine tumors: pathologic and molecular characteristics. Semin Diagn Pathol. 2014;31(6):498–511. https://doi.org/10.1053/j.semdp.2014.08.008.

    Article  PubMed  Google Scholar 

  25. Yachida S, Vakiani E, White CM, Zhong Y, Saunders T, Morgan R, et al. Small cell and large cell neuroendocrine carcinomas of the pancreas are genetically similar and distinct from well-differentiated pancreatic neuroendocrine tumors. Am J Surg Pathol. 2012;36(2):173–84. https://doi.org/10.1097/PAS.0b013e3182417d36.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Konukiewitz B, Schlitter AM, Jesinghaus M, Pfister D, Steiger K, Segler A, et al. Somatostatin receptor expression related to TP53 and RB1 alterations in pancreatic and extrapancreatic neuroendocrine neoplasms with a Ki67-index above 20. Mod Pathol. 2017;30(4):587–98. https://doi.org/10.1038/modpathol.2016.217.

    CAS  Article  PubMed  Google Scholar 

  27. Tang LH, Basturk O, Sue JJ, Klimstra DS. A practical approach to the classification of WHO grade 3 (G3) well-differentiated neuroendocrine tumor (WD-NET) and poorly differentiated neuroendocrine carcinoma (PD-NEC) of the pancreas. Am J Surg Pathol. 2016;40(9):1192–202. https://doi.org/10.1097/PAS.0000000000000662.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Elvebakken H PA, Scoazec JY, Tang LH, Federspiel B, Vestermark L, Zlobec I, Hjortland GO, Langer SW, Gronbaek H, Tiensuu Janson E, Sorbye H. A consensus developed morphological re-evaluation of 196 cases with metastatic high-grade gastroenteropancreatic neuroendocrine neoplasms (GEP-NEN G3) from the Nordic NEC Registries: consequences for classification, treatment response and survival. Presented at the 16th Annual ENETS conference in Barcelona, Spain, March 2019.

  29. Velayoudom-Cephise FL, Duvillard P, Foucan L, Hadoux J, Chougnet CN, Leboulleux S, et al. Are G3 ENETS neuroendocrine neoplasms heterogeneous? Endocr Relat Cancer. 2013;20(5):649–57. https://doi.org/10.1530/ERC-13-0027.

    Article  PubMed  Google Scholar 

  30. Bergsland EK, Roy R, Stephens P, Ross JS, Bailey M, Olshen A. Genomic profiling to distinguish poorly differentiated neuroendocrine carcinomas arising in different sites. J Clin Oncol. 2016;34(15_suppl):4020. https://doi.org/10.1200/JCO.2016.34.15_suppl.4020.

    Article  Google Scholar 

  31. Hijioka S, Hosoda W, Matsuo K, Ueno M, Furukawa M, Yoshitomi H, et al. Rb loss and KRAS mutation are predictors of the response to platinum-based chemotherapy in pancreatic neuroendocrine neoplasm with grade 3: a Japanese multicenter pancreatic NEN-G3 study. Clin Cancer Res. 2017;23(16):4625–32. https://doi.org/10.1158/1078-0432.CCR-16-3135.

    CAS  Article  Google Scholar 

  32. Hadoux J, Malka D, Planchard D, Scoazec JY, Caramella C, Guigay J, et al. Post-first-line FOLFOX chemotherapy for grade 3 neuroendocrine carcinoma. Endocr Relat Cancer. 2015;22(3):289–98. https://doi.org/10.1530/ERC-15-0075.

    CAS  Article  PubMed  Google Scholar 

  33. Fine RL, Gulati AP, Krantz BA, Moss RA, Schreibman S, Tsushima DA, et al. Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: the Pancreas Center at Columbia University experience. Cancer Chemother Pharmacol. 2013;71(3):663–70. https://doi.org/10.1007/s00280-012-2055-z.

    CAS  Article  PubMed  Google Scholar 

  34. Kulke MH, Stuart K, Enzinger PC, Ryan DP, Clark JW, Muzikansky A, et al. Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol. 2006;24(3):401–6. https://doi.org/10.1200/JCO.2005.03.6046.

    CAS  Article  PubMed  Google Scholar 

  35. Strosberg JR, Fine RL, Choi J, Nasir A, Coppola D, Chen DT, et al. First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer. 2011;117(2):268–75. https://doi.org/10.1002/cncr.25425.

    CAS  Article  PubMed  Google Scholar 

  36. Kunz PL, Catalano PJ, Nimeiri H, Fisher GA, Longacre TA, Suarez CJ, et al. A randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors: a trial of the ECOG-ACRIN Cancer Research Group (E2211). J Clin Oncol. 2018;36(15_suppl):4004. https://doi.org/10.1200/JCO.2018.36.15_suppl.4004.

    Article  Google Scholar 

  37. Sahu A, Jefford M, Lai-Kwon J, Thai A, Hicks RJ, Michael M. CAPTEM in metastatic well-differentiated intermediate to high grade neuroendocrine tumors: a single centre experience. J Oncol. 2019;2019:7. https://doi.org/10.1155/2019/9032753.

    Article  Google Scholar 

  38. Rogowski W, Wachula E, Gorzelak A, Lebiedzinska A, Sulzyc-Bielicka V, Izycka-Swieszewska E, et al. Capecitabine and temozolomide combination for treatment of high-grade well-differentiated neuroendocrine tumour and poorly-differentiated neuroendocrine carcinoma. Retrospective analysis. Endokrynol Pol. 2019. https://doi.org/10.5603/EP.a2019.0010.

  39. Chan D, Bergsland EK, Chan JA, Gadgil R, Halfdanarson TR, Hornbacker K, et al. Temozolomide in grade III neuroendocrine neoplasms (G3 NENs): a multicenter retrospective review. J Clin Oncol. 2019;37(4_suppl):321. https://doi.org/10.1200/JCO.2019.37.4_suppl.321.

    Article  Google Scholar 

  40. Yao JC, Fazio N, Singh S, Buzzoni R, Carnaghi C, Wolin E, et al. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet. 2016;387(10022):968–77. https://doi.org/10.1016/S0140-6736(15)00817-X.

    CAS  Article  PubMed  Google Scholar 

  41. Yao JC, Phan AT, Chang DZ, Wolff RA, Hess K, Gupta S, et al. Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. J Clin Oncol. 2008;26(26):4311–8. https://doi.org/10.1200/JCO.2008.16.7858.

    Article  PubMed  PubMed Central  Google Scholar 

  42. Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011;364(6):514–23. https://doi.org/10.1056/NEJMoa1009290.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  43. FDA U. Everolimus FDA approval. 2016.

  44. Fonseca PJ, Uriol E, Galvan JA, Alvarez C, Perez Q, Villanueva N, et al. Prolonged clinical benefit of everolimus therapy in the management of high-grade pancreatic neuroendocrine carcinoma. Case Rep Oncol. 2013;6(2):441–9. https://doi.org/10.1159/000354754.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  45. Scharf M, Mueller D, Koenig U, Pfestroff A, Nimphius W, Figiel J, et al. Management of a metastasized high grade insulinoma (G3) with refractory hypoglycemia: case report and review of the literature. Pancreatology. 2014;14(6):542–5. https://doi.org/10.1016/j.pan.2014.07.011.

    Article  PubMed  Google Scholar 

  46. Tanaka H, Matsusaki S, Baba Y, Isono Y, Kumazawa H, Sase T, et al. Neuroendocrine tumor G3: a pancreatic well-differentiated neuroendocrine tumor with a high proliferative rate. Clin J Gastroenterol. 2015;8(6):414–20. https://doi.org/10.1007/s12328-015-0609-4.

    Article  PubMed  Google Scholar 

  47. Panzuto F, Rinzivillo M, Spada F, Antonuzzo L, Ibrahim T, Campana D, et al. Everolimus in pancreatic neuroendocrine carcinomas G3. Pancreas. 2017;46(3):302–5. https://doi.org/10.1097/MPA.0000000000000762.

    CAS  Article  PubMed  Google Scholar 

  48. Raymond E, Dahan L, Raoul JL, Bang YJ, Borbath I, Lombard-Bohas C, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011;364(6):501–13. https://doi.org/10.1056/NEJMoa1003825.

    CAS  Article  Google Scholar 

  49. Faivre S, Niccoli P, Castellano D, Valle JW, Hammel P, Raoul JL, et al. Sunitinib in pancreatic neuroendocrine tumors: updated progression-free survival and final overall survival from a phase III randomized study. Ann Oncol. 2017;28(2):339–43. https://doi.org/10.1093/annonc/mdw561.

    CAS  Article  PubMed  Google Scholar 

  50. Pellat A, Dreyer C, Couffignal C, Walter T, Lombard-Bohas C, Niccoli P, et al. Clinical and biomarker evaluations of sunitinib in patients with grade 3 digestive neuroendocrine neoplasms. Neuroendocrinology. 2018;107(1):24–31. https://doi.org/10.1159/000487237.

    CAS  Article  PubMed  Google Scholar 

  51. Mizuno Y, Kudo A, Akashi T, Akahoshi K, Ogura T, Ogawa K, et al. Sunitinib shrinks NET-G3 pancreatic neuroendocrine neoplasms. J Cancer Res Clin Oncol. 2018;144(6):1155–63. https://doi.org/10.1007/s00432-018-2636-2.

    CAS  Article  PubMed  Google Scholar 

  52. Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, et al. Phase 3 trial of (177)Lu-Dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376(2):125–35. https://doi.org/10.1056/NEJMoa1607427.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  53. Carlsen EA, Fazio N, Granberg D, Grozinsky-Glasberg S, Ahmadzadehfar H, Grana CM, et al. Peptide receptor radionuclide therapy in gastroenteropancreatic NEN G3: a multicenter cohort study. Endocr Relat Cancer. 2019;26(2):227–39. https://doi.org/10.1530/ERC-18-0424.Very important retrospective study showing the efficacy of PRRT in NET G3.

  54. Nicolini S, Severi S, Ianniello A, Sansovini M, Ambrosetti A, Bongiovanni A, et al. Investigation of receptor radionuclide therapy with (177)Lu-DOTATATE in patients with GEP-NEN and a high Ki-67 proliferation index. Eur J Nucl Med Mol Imaging. 2018;45(6):923–30. https://doi.org/10.1007/s00259-017-3925-8.

    CAS  Article  PubMed  Google Scholar 

  55. Thang SP, Lung MS, Kong G, Hofman MS, Callahan J, Michael M, et al. Peptide receptor radionuclide therapy (PRRT) in European Neuroendocrine Tumour Society (ENETS) grade 3 (G3) neuroendocrine neoplasia (NEN) - a single-institution retrospective analysis. Eur J Nucl Med Mol Imaging. 2018;45(2):262–77. https://doi.org/10.1007/s00259-017-3821-2.

    CAS  Article  PubMed  Google Scholar 

  56. Zhang J, Kulkarni HR, Singh A, Niepsch K, Muller D, Baum RP. Peptide receptor radionuclide therapy in grade 3 neuroendocrine neoplasms: safety and survival analysis in 69 patients. J Nucl Med. 2019;60(3):377–85. https://doi.org/10.2967/jnumed.118.215848.

    CAS  Article  PubMed  Google Scholar 

  57. D’Angelo SP, Russell J, Lebbe C, Chmielowski B, Gambichler T, Grob JJ, et al. Efficacy and safety of first-line avelumab treatment in patients with stage iv metastatic Merkel cell carcinoma: a preplanned interim analysis of a clinical trial. JAMA Oncol. 2018;4(9):e180077. https://doi.org/10.1001/jamaoncol.2018.0077.

    Article  PubMed  PubMed Central  Google Scholar 

  58. Nghiem PT, Bhatia S, Lipson EJ, Kudchadkar RR, Miller NJ, Annamalai L, et al. PD-1 blockade with pembrolizumab in advanced Merkel-cell carcinoma. N Engl J Med. 2016;374(26):2542–52. https://doi.org/10.1056/NEJMoa1603702.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  59. Horn L, Mansfield AS, Szczesna A, Havel L, Krzakowski M, Hochmair MJ, et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med. 2018;379(23):2220–9. https://doi.org/10.1056/NEJMoa1809064.

    CAS  Article  PubMed  Google Scholar 

  60. Strosberg JR, Mizuno N, Doi T, Grande E, Delord J-P, Shapira-Frommer R, et al. Pembrolizumab treatment of advanced neuroendocrine tumors: results from the phase II KEYNOTE-158 study. J Clin Oncol. 2019;37(4_suppl):190. https://doi.org/10.1200/JCO.2019.37.4_suppl.190.

    Article  Google Scholar 

  61. Scarpa A, Chang DK, Nones K, Corbo V, Patch AM, Bailey P, et al. Whole-genome landscape of pancreatic neuroendocrine tumours. Nature. 2017;543(7643):65–71. https://doi.org/10.1038/nature21063.

    CAS  Article  PubMed  Google Scholar 

  62. Furlan D, Sahnane N, Mazzoni M, Pastorino R, Carnevali I, Stefanoli M, et al. Diagnostic utility of MS-MLPA in DNA methylation profiling of adenocarcinomas and neuroendocrine carcinomas of the colon-rectum. Virchows Arch. 2013;462(1):47–56. https://doi.org/10.1007/s00428-012-1348-2.

    CAS  Article  PubMed  Google Scholar 

  63. La Rosa S, Marando A, Furlan D, Sahnane N, Capella C. Colorectal poorly differentiated neuroendocrine carcinomas and mixed adenoneuroendocrine carcinomas: insights into the diagnostic immunophenotype, assessment of methylation profile, and search for prognostic markers. Am J Surg Pathol. 2012;36(4):601–11. https://doi.org/10.1097/PAS.0b013e318242e21c.

    Article  PubMed  Google Scholar 

  64. Sahnane N, Furlan D, Monti M, Romualdi C, Vanoli A, Vicari E, et al. Microsatellite unstable gastrointestinal neuroendocrine carcinomas: a new clinicopathologic entity. Endocr Relat Cancer. 2015;22(1):35–45. https://doi.org/10.1530/ERC-14-0410.

    CAS  Article  PubMed  Google Scholar 

  65. Volante M, Monica V, Birocco N, Brizzi MP, Busso S, Daniele L, et al. Expression analysis of genes involved in DNA repair or synthesis in mixed neuroendocrine/nonneuroendocrine carcinomas. Neuroendocrinology. 2015;101(2):151–60. https://doi.org/10.1159/000375449.

    CAS  Article  PubMed  Google Scholar 

  66. Vijayvergia N, Dasari A, Ross EA, Dotan E, Halperin DM, Astsaturov IA, et al. Pembrolizumab (P) monotherapy in patients with previously treated metastatic high grade neuroendocrine neoplasms (HG-NENs). J Clin Oncol. 2018;36(15_suppl):4104. https://doi.org/10.1200/JCO.2018.36.15_suppl.4104.

    Article  Google Scholar 

  67. J.C. Yao, J. Strosberg, N. Fazio, M.E. Pavel, P. Ruszniewski, E. Bergsland, D. Li, S. Tafuto, N. Raj, D. Campana, S. Hijioka, M. Raderer, R. Guimbaud, P. Gajate, S. Pusceddu, A. Reising, E. Degtyarev, B. Mookerjee, P. Aimone, S. Singh. Activity & safety of spartalizumab (PDR001) in patients (pts) with advanced neuroendocrine tumors (NET) of pancreatic (Pan), gastrointestinal (GI), or thoracic (T) origin, & gastroenteropancreatic neuroendocrine carcinoma (GEP NEC) who have progressed on prior treatment (Tx) ESMO. 2018. Presented at the 2018 annual European Society for Medical Oncology in Munich, Germany, 2018. https://oncologypro.esmo.org/Meeting-Resources/ESMO-2018-Congress/Activity-Safety-of-Spartalizumab-PDR001-in-Patients-pts-With-Advanced-Neuroendocrine-Tumors-NET-of-Pancreatic-Pan-Gastrointestinal-GI-or-Thoracic-T-Origin-Gastroenteropancreatic-Neuroendocrine-Carcinoma-GEP-NEC-Who-Have-Progressed-on

  68. Patel SP. CT039 - A phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) S1609: the neuroendocrine cohort. 2019. Presented at the 2019 Annual Conference of the American Association for Cancer Research (AACR) in Atlanta, Georgia, USA, 2019.

  69. Coriat R, Walter T, Terris B, Couvelard A, Ruszniewski P. Gastroenteropancreatic well-differentiated grade 3 neuroendocrine tumors: review and position statement. Oncologist. 2016;21(10):1191–9. https://doi.org/10.1634/theoncologist.2015-0476.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  70. Galleberg RB, Knigge U, Tiensuu Janson E, Vestermark LW, Haugvik SP, Ladekarl M, et al. Results after surgical treatment of liver metastases in patients with high-grade gastroenteropancreatic neuroendocrine carcinomas. Eur J Surg Oncol. 2017;43(9):1682–9. https://doi.org/10.1016/j.ejso.2017.04.010.

    CAS  Article  PubMed  Google Scholar 

  71. Crippa S, Partelli S, Bassi C, Berardi R, Capelli P, Scarpa A, et al. Long-term outcomes and prognostic factors in neuroendocrine carcinomas of the pancreas: morphology matters. Surgery. 2016;159(3):862–71. https://doi.org/10.1016/j.surg.2015.09.012.

    Article  PubMed  Google Scholar 

  72. Du S, Wang Z, Sang X, Lu X, Zheng Y, Xu H, et al. Surgical resection improves the outcome of the patients with neuroendocrine tumor liver metastases: large data from Asia. Medicine (Baltimore). 2015;94(2):e388. https://doi.org/10.1097/MD.0000000000000388.

    Article  Google Scholar 

Download references

Author information

Affiliations

  1. Mayo Clinic Cancer Center, Phoenix, AZ, USA

    Mohamad Bassam Sonbol MD

  2. Mayo Clinic Cancer Center, 200 1st St SW, Rochester, MN, 55905, USA

    Thorvardur R. Halfdanarson MD

Authors
  1. Mohamad Bassam Sonbol MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Thorvardur R. Halfdanarson MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Thorvardur R. Halfdanarson MD.

Ethics declarations

Conflict of Interest

Mohamad Bassam Sonbol declares that he has no conflict of interest. Thorvardur R. Halfdanarson has received research funding from Ipsen and has served on advisory boards for Curium and Lexicon Pharmaceuticals. Research funding from Thermo Fisher Scientific

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Neuroendocrine Cancers

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Sonbol, M.B., Halfdanarson, T.R. Management of Well-Differentiated High-Grade (G3) Neuroendocrine Tumors. Curr. Treat. Options in Oncol. 20, 74 (2019). https://doi.org/10.1007/s11864-019-0670-1

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11864-019-0670-1

Keywords

  • Neuroendocrine carcinoma
  • Neuroendocrine neoplasm
  • Neuroendocrine tumor
  • High-grade
  • PRRT